Press Release: NewGen Reports Nine-Month 2025 Results with Balance Sheet Strengthened to $66.75 Net Asset Value Per Share

Dow Jones
Yesterday

BANGKOK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) ("NewGen" or "the Company"), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today reported its unaudited financial results for the nine months ended September 30, 2025.

Financial Highlights for the Nine Months Ended September 30, 2025

   -- Net income attributable to the shareholders of the Company was $17.5 
      million, a significant improvement from a net loss of $416,400 in the 
      same period of 2024. This was primarily due to a non-cash, bargain 
      purchase gain recognized on the acquisition of Nodexus and Microsort 
      businesses. 
 
   -- Basic earnings per share was $96.76 for the nine months ended September 
      30, 2025 while losses per share for the nine months ended September 30, 
      2024 was $205.97. 
 
   -- Net book value per share improved to $66.75 from negative net book value 
      as of December 31, 2024, representing a significant balance sheet 
      transformation driven by strategic acquisitions of high-value 
      intellectual property assets. 

Business Highlights for the Nine Months Ended September 30, 2025

The Company has made significant progress in executing its strategic pivot and diversification strategy throughout 2025. Key initiatives and achievements demonstrating this progress include:

   -- Transformative Acquisitions: The Company completed two key acquisitions. 
 
          -- On February 28, 2025, the Company acquired the MicroSort$(R)$ 
             sperm-sorting technology, enhancing its capabilities in the 
             fertility services market. The acquisition also resulted in a 
             prior bargain purchase gain of $4.28 million based on an 
             independent valuation report. 
 
          -- On July 29, 2025, the Company acquired advanced cytometry 
             intellectual property and equipment from Nodexus. An independent 
             valuation by a "big-four" accounting firm received in October 2025 
             confirmed a fair value of $17.9 million for the IP, resulting in a 
             total bargain purchase gain of $19.16 million. This acquisition is 
             central to the Company's pivot towards a high-margin, 
             technology-licensing business model. 
 
   -- 2025 Debt Financing: On April 1, 2025, the Company entered into a 
      Securities Purchase Agreement for the issuance of senior convertible 
      notes with an aggregate principal amount of up to $28.8 million. The 
      first tranche of $3.2 million was received on June 3, 2025, providing 
      capital to fund our strategic initiatives. 
 
   -- Expansion into Digital Assets: The Company is actively building its 
      digital asset portfolio, including a plan to invest in Solana $(SOL)$. On 
      June 2, 2025, the Company announced a plan to invest up to $30 million in 
      SOL, and has, as of November 28, 2025, acquired 13,000.23 SOL. The 
      Company has also been engaged to tokenize a $2 million private art 
      collection and a $100 million tranche of gold-backed assets, representing 
      new, potentially high-margin revenue streams. 
 
   -- Strategic Joint Venture in UAE Real Estate: Through its subsidiary, and 
      as disclosed on October 8, 2025, the Company entered into a joint venture 
      to develop a strategic plot of land in Ras Al Khaimah, UAE, securing a 
      60% ownership interest and is positioned to benefit from the project's 
      gross revenue. 
 
   -- Proposed Reverse Merger: The Company is exploring a potential reverse 
      merger with SAXA, Inc., which would provide access to a portfolio of 
      mining assets, including a validated gold and silver mine. 
 
   -- Share Repurchase Program: In November 2025, the Company's Board of 
      Directors authorized a share repurchase program of up to $2 million over 
      24 months, reflecting management's confidence in the intrinsic value of 
      the Company. 
 
   -- Reverse Stock Split: On November 10, 2025, the Company announced a 
      one-for-five reverse stock split of its issued and unissued shares (the 
      "Reverse Stock Split"). The Reverse Stock Split became effective on 
      Monday, December 1, 2025 and the Company's Class A Ordinary Shares began 
      trading on the Nasdaq Capital Market on a split-adjusted basis at the 
      opening of market on December 1, 2025. 

Management Commentary

Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, commented, "The nine months ended September 30, 2025 represent an important period for NewGen, with net income of $17.5 million compared to a net loss in the prior year. This improvement was driven by our strategic focus on acquiring high-value intellectual property. The acquisition of Nodexus business including but not limited to advanced cytometry IP generated a bargain purchase gain and increased our net asset value per share to $66.75, positioning us as a technology-driven company with a licensing model that we can scale globally."

"Beyond this core transformation, we embraced the execution of a diversified growth strategy across multiple high-potential sectors. Our digital asset initiatives include strategic Solana treasury positioning and exclusive tokenization mandates in art- and gold-backed assets, representing significant new revenue opportunities. Meanwhile, our UAE real estate joint venture provides direct access to promising Middle Eastern development projects with attractive revenue-sharing terms. Combined with our newly reinforced balance sheet, we believe this unique combination of proprietary technology assets, strategic market positioning, and strong execution creates compelling long-term value for our shareholders."

Nine Months Ended September 30, 2025 Financial Results

   -- Revenues: Total revenues were $3.3 million for the nine months ended 
      September 30, 2025, compared to $4.2 million from the same period 2024. 
 
   -- Cost of Revenues: Cost of revenues was unchanged at $2.9 million, 
      compared to the previous year. 
 
   -- Total Other Income: Total other income, net, was $23.20 million for the 
      nine months ended September 30, 2025, a substantial improvement from 
      other losses, net, $346,748 in the prior year period. This was primarily 
      due to a non-cash, bargain purchase gain of $23.44 million recognized on 
      the acquisition of Nodexus and Microsort businesses including but not 
      limited to its intellectual property and trademarks based on two 
      independent valuation reports. 
 
   -- General and Administrative Expenses: General and administrative expenses 
      were $5.7 million, compared to $1.1 million for the nine months ended 
      September 30, 2024. The increase was primarily attributable to costs 
      associated with supporting the Company's expanding strategic initiatives 
      and corporate development activities. 
 
   -- Net Income: Net income attributable to the shareholders of the Company 
      was $17.5 million, a significant improvement from a net loss of $416,400 
      in the same period of 2024. This result was primarily driven by a $23.44 
      million gain from bargain purchases on acquisitions. 

About NewGenIvf Group Limited

NewGenIvf Group Limited (NASDAQ: NIVF) is a tech-forward, diversified, multi-jurisdictional company transforming industries through innovative solutions. The Company is strategically pivoting from its foundation in fertility services to a technology-driven model centered on the licensing of proprietary reproductive technologies. This core is augmented by strategic growth vectors in digital asset management, including tokenization services and a Solana treasury strategy, and real estate development through a joint venture in the UAE. NewGen is focused on building a high-growth, diversified ecosystem that leverages blockchain technology and strategic acquisitions to drive long-term shareholder value.

Safe Harbor Statements

This news release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "going forward," "outlook," and similar statements. Forward-looking statements in this 6-K include, but are not limited to, statements regarding: (i) the Company's strategic pivot to a technology-licensing business model and its ability to generate licensing revenue from acquired intellectual property; (ii) plans to invest in digital assets, including Solana, and the Company's digital asset treasury strategy; (iii) tokenization services and revenue opportunities related to art collections and gold-backed assets; (iv) the anticipated benefits and revenue potential from the UAE real estate joint venture; (v) the potential reverse merger with SAXA, Inc and access to mining assets; (vi) the Company's diversified growth strategy and ability to execute across multiple business sectors; and (vii) the Company's financial condition, liquidity, and ability to fund its strategic initiatives.

These forward-looking statements are based on management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties, and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to: (i) the Company's ability to successfully commercialize and license acquired intellectual property; (ii) uncertainty regarding the actual fair value of acquired intangible assets and potential future impairment charges; (iii) risks that independent valuations may not reflect actual market value or revenue generating potential; (iv) regulatory requirements and restrictions affecting reproductive technologies in various jurisdictions; (v) extreme volatility in digital asset markets, including Solana; (vi) the Company's limited operating history in multiple new business segments and unproven business models; (vii) management's ability to effectively oversee business operations across multiple jurisdictions; (viii) uncertainties regarding the ability to fund, develop, obtain permits and complete the UAE real estate project; and (ix) the Company's ability to secure additional financing on favorable terms or at all. The risks and uncertainties described above are not exhaustive. Additional risks and uncertainties not presently known to the Company may also adversely affect the Company's business, financial condition, results of operations, and prospects. These factors may cause the Company's actual results, performance, or achievements to differ materially from those in the forward-looking statements. Investors are urged to carefully review and consider the various disclosures made by the Company in this release and in the Company's periodic reports filed with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required under applicable law. Readers should not rely upon the information in this news release as current or accurate after its publication date.

For more information:

Investor Relations Contact

ICR, LLC

Robin Yang

Phone: +1 (212) 537-4406

Email: Newgenivf.IR@icrinc.com

 
                        NEWGENIVF GROUP LIMITED 
                  UNAUDITED CONSOLIDATED BALANCE SHEETS 
                         (Stated in US Dollars) 
                                      September 30,     December 31, 
                                          2025              2024 
                                     ---------------   -------------- 
                                       (unaudited)       (audited) 
ASSETS 
Current assets 
     Cash and cash equivalents        $      295,289    $     457,740 
     Accounts receivable, net                185,907           49,245 
     Inventories                              86,977           80,813 
     Deposits, prepayments and 
      other receivables, net                 951,046          195,446 
     Deposit with a digital asset 
      trading platform                     2,674,042        1,000,000 
     Receivable from agents                1,272,640        1,191,795 
     Prepayments                                 ---          197,706 
     Due from related parties                 89,973               -- 
                                         -----------       ---------- 
Total current assets                       5,555,874        3,172,745 
                                         -----------       ---------- 
 
Non-current assets 
     Plant and equipment, net                329,360          273,096 
     Right-of-use assets, net                846,335           98,570 
     Intangible assets                    24,242,555              --- 
     Investment in Artwork                   270,000              --- 
     Financial Assets                        262,712 
     Deferred legal and 
     professional fees                       196,623              --- 
     Other receivable, deposit and 
      other receivables, net               3,854,609           33,333 
     Taxes recoverable                           326              --- 
                                         -----------       ---------- 
Total non-current assets                  30,002,520          404,999 
                                         -----------       ---------- 
TOTAL ASSETS                          $   35,558,394    $   3,577,744 
                                         ===========       ========== 
 
LIABILITIES AND SHAREHOLDERS' 
EQUITY 
Current liabilities 
     Accounts payable                 $      797,718    $   1,298,964 
     Accrued liabilities and other 
      payables                               450,341          500,729 
     Contract liabilities                     67,401           63,489 
     Due to related parties                      ---          154,453 
     Operating lease liabilities, 
      current                                305,518          108,526 
     Convertible notes                            --           82,447 
     Promissory note                              --          500,000 
     Taxes payable                                --           11,746 
                                         -----------       ---------- 
Total current liabilities                  1,620,978        2,720,354 
                                         -----------       ---------- 
Non-current liabilities 
     Operating lease liabilities, 
      non-current                            298,081           10,231 
     Convertible notes, non-current        4,900,000        2,328,916 
                                         -----------       ---------- 
 
Total non-current liabilities              5,198,081        2,339,147 
                                         -----------       ---------- 
Total liabilities                     $    6,819,059    $   5,059,501 
                                         -----------       ---------- 
 
Shareholders' equity 
      Ordinary shares, no par 
      value, unlimited authorized 
      shares and 430,540* and 
      2,030* shares issued and 
      outstanding as of September 
      30, 2025 and December 31, 
      2024 respectively                           --               -- 
     Subscription receivable                      --         (204,000) 
     Additional paid-in capital           13,063,507          122,505 
     Retained Earnings / 
      (Accumulated deficit)               16,562,336         (985,994) 
     Accumulated other 
      comprehensive (loss) income           (249,711)          18,875 
                                         -----------       ---------- 
Equity attributable to the 
 shareholders of the Company              29,376,132       (1,048,614) 
     Non-controlling interests              (636,797)        (433,143) 
                                         -----------       ---------- 
Total shareholders' equity                28,739,335       (1,481,757) 
                                         -----------       ---------- 
 
TOTAL LIABILITIES AND SHAREHOLDERS' 
 EQUITY                               $   35,558,394    $   3,577,744 
                                         ===========       ========== 
 

The accompanying notes are an integral part of these consolidated financial statements.

 
*  The shares as presented have been adjusted retrospectively 
    for Reverse Share Splits effected in February 2025 
    of 1 share for every 20 existing shares issued, in 
    May 2025 of 1 share for every 10 existing share issued, 
    in August 2025 of 1 share for every 5 shares issued 
    and in December 2025 of 1 share for every 5 shares 
    issued respectively. 
 
 
                        NEWGENIVF GROUP LIMITED 
        UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS 
                                   AND 
                       COMPREHENSIVE (LOSS) INCOME 
                         (Stated in US Dollars) 
                                            Nine Months Ended 
                                    --------------------------------- 
                                     September 30,     September 30, 
                                          2025              2024 
                                    ---------------   --------------- 
Revenues                             $    3,301,879    $    4,159,763 
Cost of revenues                         (2,870,058)       (2,872,004) 
                                        -----------       ----------- 
Gross profit                                431,821         1,287,759 
 
Operating expenses 
Selling and marketing expenses             (494,388)         (192,276) 
General and administrative 
 expenses                                (5,690,300)       (1,166,858) 
                                        -----------       ----------- 
 
Total operating expenses                 (6,184,688)       (1,359,134) 
                                        -----------       ----------- 
 
Operating income (loss)                  (5,752,867)          (71,375) 
                                        -----------       ----------- 
 
Other income (expenses), net 
   Other income, net                     23,370,460             8,404 
   Interest income                            2,003             2,399 
   Interest expense                        (173,583)         (357,551) 
                                        -----------       ----------- 
Total other income (expenses), net       23,198,880          (346,748) 
                                        -----------       ----------- 
 
Income (loss) before taxes               17,446,013          (418,123) 
Provision for income taxes                      ---               --- 
                                        -----------       ----------- 
Net income (loss)                        17,446,013          (418,123) 
Less: net loss attributable to 

(MORE TO FOLLOW) Dow Jones Newswires

December 02, 2025 08:00 ET (13:00 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10